|Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia …|
JP McEvoy, JM Meyer, DC Goff, HA Nasrallah, SM Davis, L Sullivan, ...
Schizophrenia research 80 (1), 19-32, 2005
|The emerging role of glutamate in the pathophysiology and treatment of schizophrenia|
DC Goff, JT Coyle
American Journal of Psychiatry 158 (9), 1367-1377, 2001
|Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study|
DC Henderson, E Cagliero, C Gray, RA Nasrallah, DL Hayden, ...
American Journal of Psychiatry 157 (6), 975-981, 2000
|Regionally localized thinning of the cerebral cortex in schizophrenia|
GR Kuperberg, MR Broome, PK McGuire, AS David, M Eddy, F Ozawa, ...
Archives of general psychiatry 60 (9), 878-888, 2003
|Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects.|
DC Goff, DC Henderson, E Amico
The American journal of psychiatry, 1992
|Impaired recruitment of the hippocampus during conscious recollection in schizophrenia|
S Heckers, S Rauch, D Goff, C Savage, D Schacter, A Fischman, N Alpert
Nature neuroscience 1 (4), 318-323, 1998
|Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline|
HA Nasrallah, JM Meyer, DC Goff, JP McEvoy, SM Davis, TS Stroup, ...
Schizophrenia research 86 (1-3), 15-22, 2006
|A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls|
DC Goff, LM Sullivan, JP McEvoy, JM Meyer, HA Nasrallah, GL Daumit, ...
Schizophrenia research 80 (1), 45-53, 2005
|Schizophrenic subjects show aberrant fMRI activation of dorsolateral prefrontal cortex and basal ganglia during working memory performance|
DS Manoach, RL Gollub, ES Benson, MM Searl, DC Goff, E Halpern, ...
Biological psychiatry 48 (2), 99-109, 2000
|Cognitive therapy for psychosis in schizophrenia: an effect size analysis|
RA Gould, KT Mueser, E Bolton, V Mays, D Goff
Focus 48 (1), 335-101, 2004
|A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia|
RW Buchanan, M Davis, D Goff, MF Green, RSE Keefe, AC Leon, ...
Schizophrenia bulletin 31 (1), 5-19, 2005
|A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia|
DC Goff, G Tsai, J Levitt, E Amico, D Manoach, DA Schoenfeld, ...
Archives of general psychiatry 56 (1), 21-27, 1999
|Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia|
JT Coyle, G Tsai, D Goff
Annals of the New York Academy of Sciences 1003 (1), 318-327, 2003
|Schizophrenic subjects activate dorsolateral prefrontal cortex during a working memory task, as measured by fMRI|
DS Manoach, DZ Press, V Thangaraj, MM Searl, DC Goff, E Halpern, ...
Biological psychiatry 45 (9), 1128-1137, 1999
|Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis|
DC Henderson, E Cagliero, PM Copeland, CP Borba, AE Evins, ...
Archives of general psychiatry 62 (1), 19-28, 2005
|Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists|
DC Goff, C Cather, AE Evins, DC Henderson, O Freudenreich, ...
The Journal of clinical psychiatry 66 (2), 183-194, 2005
|Reduced sleep spindles and spindle coherence in schizophrenia: mechanisms of impaired memory consolidation?|
EJ Wamsley, MA Tucker, AK Shinn, KE Ono, SK McKinley, AV Ely, ...
Biological psychiatry 71 (2), 154-161, 2012
|Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1|
JM Meyer, VG Davis, DC Goff, JP McEvoy, HA Nasrallah, SM Davis, ...
Schizophrenia research 101 (1-3), 273-286, 2008
|Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations|
O Freudenreich, DC Goff
Acta Psychiatrica Scandinavica 106 (5), 323-330, 2002
|Dose-finding trial for D-cycloserine added to neuroleptics for negative symptoms in schizophrenia.|
DC Goff, G Tsai, DS Manoach, JT Coyle
The American journal of psychiatry, 1995